News and Updates
Dr. Bala Ambati, President and Founder of iVeena, provides update of iVeena activities at the recent OIS (Ophthalmology Innovation Summit) meeting in Washington, DC.
View the presentation at https://www.youtube.com/embed/mZqwcWkOmzE
iVeena receives Notice of Allowance from the US Patent Office for patent protecting cataract implants (IVMED 10&20).
Salt Lake City, Utah,--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a biopharmaceutical company that develops innovative ophthalmology products, today announced that the United States Patent and
iVeena Receives FDA Orphan Drug Designation for IVMED-80 for the Treatment of Keratoconus
iVeena announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IVMED-80, for the treatment of keratoconus. Keratoconus is a degenerative disorder causing a c
iVeena Completes Phase I/2a Pilot Clinical Study of IVMED-10, a Bioerodable, Sustained Release, Intracapsular Implant to Treat Inflammation and Pain Associated with Cataract Surgery
iVeena Completes Phase 1/2a Pilot Clinical Study for IVMED-10, a Bioerodable, Sustained Release, Intracapsular Implant that Delivers Dexamethasone to Both Anterior and Posterior Eye Segments to Treat
iVeena has been awarded a total of $450K in NSF and NIH grants to advance its Keratoconus Orphan Drug candidate and Gene Therapy programs.
"iVeena is pleased to receive a total of $450K in Federal Government grants to advance its portfolio programs," said Gerald Simmons, CEO. "$225K is an NIH grant for its Keratoconus Orphan Drug candida
Page 5 of 9